Global Frontier Pharma Report 2015: Versatile Innovation in Oncology - A Number of Highly Promising First-in-Class Versatile Oncology Pipeline Targets

Nov 12, 2015, 18:10 ET from Research and Markets

DUBLIN, Nov. 12, 2015 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation" report to their offering.

The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden.

Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages.

Due to a degree of crossover between oncology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications. Some 473 first-in-class pipeline products are in concurrent development for two or more of the top 20 cancer sites ranked by incidence.

The most promising versatile first-in-class molecular targets predominantly consist of receptor tyrosine kinases and their downstream signal transduction kinases, although a number of other cancer-related processes such as DNA repair, cancer immunosurveillance and apoptotic pathways are also targeted.

Key Topics Covered:

1 Tables & Figures

2 Executive Summary

3 The Case for Innovation in the Oncology Market

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Signaling Pathways, Disease-Causing Mutations and Versatile First-in-Class Molecular Target Integration

7 Versatile First-in-Class Target Assessment

8 Deals and Strategic Consolidations

9 Appendix

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


SOURCE Research and Markets